Auricularia and Thrombosis Prevention Research

Wood Ear Blood Health

40 Years

Auricularia's antiplatelet properties have been studied since 1982, when Agarwal et al. first showed Mo-er extracts inhibit ADP-induced platelet aggregation in human and rat platelets.

Agarwal et al., Thrombosis and Haemostasis, 1982

Aspirin-Like Effect

on platelet aggregation in ex vivo rat tests

APTT + PT + TT

all three clotting times prolonged by AAP-b2

0 Human Trials

all evidence is preclinical

Agarwal et al., Thrombosis and Haemostasis, 1982

View as image ↗

Thrombosis, the formation of blood clots inside blood vessels, is the proximate cause of most heart attacks and strokes. Auricularia auricula (wood ear mushroom, known as Mo-er in Chinese cuisine) has been investigated for antithrombotic properties since 1982, making it one of the longest-studied edible mushrooms in cardiovascular research. Five studies spanning four decades have identified specific polysaccharides that inhibit platelet aggregation, prolong coagulation times, and reduce thrombus formation in animal models through distinct molecular mechanisms. All evidence is preclinical.

For the broader cardiovascular context, see wood ear for heart health: cardiovascular research review and Auricularia and atherosclerosis prevention. For a focused look at anticoagulant mechanisms, see wood ear and anticoagulant polysaccharides: nature's blood thinner.

The 1982 Discovery: Platelet Aggregation Inhibition

Agarwal et al. (1982) published the foundational study on Auricularia's blood effects, testing hot water extracts of Mo-er against human and rat platelet aggregation.^[1] The extracts strongly inhibited ADP-induced platelet aggregation in both species.

HPLC analysis identified adenosine in two Auricularia varieties: A. auricula (133 microg/g dry weight) and A. polytricha (154 microg/g). Adenosine is a known platelet inhibitor, but the extract's antiplatelet activity exceeded what adenosine alone could explain. Three findings confirmed additional active agents beyond adenosine:

1. Mo-er extracts caused faster onset and longer duration of inhibition than equivalent amounts of adenosine
2. Treatment with adenosine deaminase (which degrades adenosine) did not eliminate the extract's antiplatelet activity
3. DDA (an adenylate cyclase inhibitor) and MTA (an adenosine receptor antagonist) only partially blocked the inhibition

The extract also inhibited rat platelet aggregation, but adenosine alone did not, confirming species-specific differences and the presence of non-adenosine active compounds. The authors concluded that Mo-er contains "an agent (or agents) in addition to Ado, that blocks platelet aggregation by a mechanism that does not involve the platelet cyclic AMP system."

This 1982 finding established Auricularia as a mushroom with genuine antiplatelet activity, but left the active compound(s) unidentified.

Identifying the Anticoagulant Polysaccharide

Twenty-one years later, Yoon et al. (2003) isolated the responsible molecule: an acidic polysaccharide from Auricularia auricula.^[2] Using water, alkali, and acid extractions followed by gel filtration chromatography, they purified a polysaccharide with specific anticoagulant activity of 2 IU/mg and an average molecular mass of approximately 160 kDa.

The polysaccharide contained mannose, glucose, glucuronic acid, and xylose but no sulfate esters. This last detail is significant: heparin, the clinical gold standard polysaccharide anticoagulant, relies entirely on sulfate groups for its activity. The Auricularia polysaccharide uses a fundamentally different structural basis for anticoagulation.

The mechanism was specific. The polysaccharide catalyzed thrombin inhibition by antithrombin (the body's primary natural anticoagulant protein) but did not enhance inhibition by heparin cofactor II (another anticoagulant protein that heparin activates). Factor Xa inhibition by antithrombin was not affected. This selectivity means the Auricularia polysaccharide targets one specific step in the coagulation cascade rather than broadly suppressing clotting.

Chemical modification experiments revealed the structural requirement: when glucuronic acid carboxyl groups were chemically reduced, all anticoagulant activity disappeared. The uronic acid residues are the functional element, not the neutral sugars.

In ex vivo rat tests, oral administration of the polysaccharide inhibited platelet aggregation at a level comparable to aspirin. This oral bioavailability is unusual for polysaccharides, which are typically poorly absorbed from the gut. Whether the polysaccharide acts systemically after absorption or locally in the gut (affecting platelet-activating factors before they reach the bloodstream) was not determined.

Structural Characterization and Extraction Optimization

Bian et al. (2020) addressed a practical bottleneck: efficient extraction of anticoagulant polysaccharides from Auricularia for potential food industry applications.^[3] Using ultrasound-assisted extraction optimized by response surface methodology, they achieved maximum crude polysaccharide yield of 14.74 mg/g at 74 degrees C, 27 minutes, 103 mL/g liquid ratio, and 198 W ultrasound power.

The acidic fraction (aAAP-1), isolated by CTAB precipitation and DEAE ion exchange chromatography, was composed of mannose, glucuronic acid, glucose, galactose, and xylose in a molar ratio of 80.63:9.88:2.25:1:31.13. Coagulation assays confirmed aAAP-1 prolonged APTT, PT, and TT, indicating synergistic anticoagulant activity through both the intrinsic (contact activation) and extrinsic (tissue factor) coagulation pathways.

This extraction work is important for translational purposes. Without efficient, reproducible extraction methods, any clinical development of Auricularia anticoagulants would be impractical. The mannose-rich composition (>80% of the sugar profile) and the consistent presence of glucuronic acid across all three polysaccharide studies suggest a conserved structural motif responsible for the anticoagulant effect.

AAP-b2: The Most Complete Antithrombotic Study

Bian et al. (2022) produced the most comprehensive antithrombotic study to date, isolating a novel polysaccharide (AAP-b2) and testing it in a carrageenan-induced mouse thrombosis model.^[4]

AAP-b2 (12.02 kDa, smaller than the 160 kDa polysaccharide from Yoon et al.) was composed of mannose, glucuronic acid, glucose, and xylose (molar ratio 89.25:30.50:4.25:1.00). NMR analysis revealed the backbone structure: primarily mannose residues with glucuronic acid branching.

In Vivo Antithrombotic Effects

In carrageenan-treated mice, AAP-b2:

• Inhibited platelet aggregation
• Reduced black tail length (a direct measure of thrombus size)
• Prolonged APTT, PT, and TT (all three standard clotting time measures)

Molecular Mechanisms

The study identified two parallel antithrombotic mechanisms:

Antiplatelet pathway: AAP-b2 regulated endothelial nitric oxide synthase (eNOS), endothelin-1 (ET-1), prostacyclin (PGI2), and thromboxane B2 (TXB2). These are the key endothelial mediators that control the balance between platelet activation (promoted by ET-1 and TXB2) and platelet inhibition (promoted by eNOS-derived NO and PGI2). AAP-b2 shifted this balance toward inhibition.

Anticoagulant pathway: AAP-b2 enhanced antithrombin III (AT-III) and protein C (PC) activity. AT-III is the same target identified by Yoon et al. (2003), confirming this mechanism across two different polysaccharide preparations. Protein C is an additional natural anticoagulant that inactivates Factors Va and VIIIa. Engaging both AT-III and protein C provides broader anticoagulant coverage than either alone.

The dual mechanism (antiplatelet plus anticoagulant) is pharmacologically notable. Aspirin inhibits platelets. Heparin is an anticoagulant. Achieving both effects from a single polysaccharide is unusual and could theoretically provide more comprehensive thrombosis protection than either mechanism alone.

Connecting the Four Decades of Evidence

The five studies form a coherent progression:

1. 1982: Auricularia extracts inhibit platelet aggregation through unknown mechanism(s) beyond adenosine
2. 2003: A 160 kDa acidic polysaccharide is identified as the anticoagulant, working through antithrombin-mediated thrombin inhibition; glucuronic acid residues are essential
3. 2020: Extraction methods are optimized; acidic polysaccharide fraction confirms anticoagulant activity through intrinsic and extrinsic pathways
4. 2022: A smaller 12 kDa polysaccharide (AAP-b2) shows combined antiplatelet and anticoagulant activity through eNOS/ET-1/PGI2/TXB2 and AT-III/protein C pathways in a mouse thrombosis model

The consistent role of mannose-rich, glucuronic acid-containing polysaccharides across these studies suggests a defined compound class rather than nonspecific extract effects. However, the molecular weight difference between the 160 kDa (Yoon) and 12 kDa (Bian) active polysaccharides raises questions about whether these are fragments of the same molecule or distinct compounds with similar mechanisms.

The molar ratios of constituent sugars are similar but not identical across preparations: Yoon's 160 kDa polysaccharide contained mannose, glucose, glucuronic acid, and xylose; Bian's AAP-b2 contained mannose (89.25%), glucuronic acid (30.50%), glucose (4.25%), and xylose (1.00%); and Bian's 2020 acidic fraction aAAP-1 contained mannose (80.63%), glucuronic acid (9.88%), galactose (1%), glucose (2.25%), and xylose (31.13%). The consistently high mannose content (80-89%) and the presence of glucuronic acid in all preparations suggest a core structural motif. The variation in minor sugars likely reflects differences in extraction conditions, purification methods, and source material rather than fundamentally different molecules.

For cardiovascular patients and clinicians, the key question is whether the in vivo antithrombotic effects seen in the Bian et al. (2022) mouse model translate to human-relevant dosing. The carrageenan-induced thrombosis model is widely used in pharmaceutical screening but produces a more acute and severe thrombotic event than the chronic atherothrombotic disease that causes most human cardiovascular events. A polysaccharide effective against acute carrageenan thrombosis may or may not prevent the slow progression of atherothrombotic plaque rupture. For comparison with pharmaceutical approaches, see wood ear vs. aspirin for blood thinning: how they compare.

What the Evidence Does Not Show

No human thrombosis data exist. All studies used rats or mice. Human platelet biology, coagulation cascade kinetics, and pharmacokinetics differ from rodents.

The aspirin comparison is limited. Yoon et al. (2003) showed aspirin-like platelet inhibition in an ex vivo rat test, but this is not equivalent to a clinical head-to-head trial. Aspirin's dose-response, duration of action, and clinical outcome data are based on trials involving hundreds of thousands of patients. Auricularia has zero human trial data.

Drug interactions are unstudied. Many cardiovascular patients take anticoagulants (warfarin, rivaroxaban, apixaban) or antiplatelet agents (aspirin, clopidogrel). Whether Auricularia polysaccharides interact with these drugs, potentially causing dangerous over-anticoagulation, has never been investigated. This is a genuine safety gap.

Oral bioavailability is poorly understood. Yoon et al. (2003) showed oral effects in rats, but the mechanism of a 160 kDa polysaccharide crossing the intestinal barrier is unclear. Large polysaccharides are generally not absorbed intact. The active form reaching the bloodstream may be a degradation fragment, a gut-mediated signaling molecule, or something else entirely.

Dose-response data are sparse. The effective dose for antithrombotic activity in humans consuming whole wood ear mushroom is unknown. The traditional Chinese practice of consuming wood ear in soup or stir-fry may or may not deliver pharmacologically relevant amounts of anticoagulant polysaccharides.

For antiplatelet research specifically, see wood ear and blood clot prevention: antiplatelet activity. For the blood health overview, see wood ear and blood health: anti-coagulant research.

The Bottom Line

Auricularia auricula produces mannose-rich, glucuronic acid-containing polysaccharides with demonstrated antithrombotic activity in animal models. Four decades of research have progressively identified the active compounds, mapped their mechanisms (antithrombin-mediated thrombin inhibition, eNOS/endothelin-1/prostacyclin/thromboxane regulation, and protein C pathway enhancement), and demonstrated in vivo thrombus reduction in mouse models. The dual antiplatelet and anticoagulant activity from a single polysaccharide class is pharmacologically unusual. All evidence remains preclinical, and the translation to human thrombosis prevention is complicated by unknown oral bioavailability, absent drug interaction data, and no human clinical trials.

Frequently Asked Questions

Does wood ear mushroom thin the blood?

Preclinical studies show Auricularia auricula polysaccharides inhibit platelet aggregation and prolong clotting times in animal models. A purified polysaccharide showed aspirin-like antiplatelet effects when fed orally to rats (Yoon et al., 2003). A novel polysaccharide AAP-b2 reduced thrombus formation in mice (Bian et al., 2022). These are animal findings; whether eating wood ear mushroom at dietary amounts produces clinically meaningful blood-thinning effects in humans is unknown.

How does Auricularia prevent blood clots?

Research identifies two parallel mechanisms. Auricularia polysaccharides catalyze thrombin inhibition through antithrombin III, the body's primary natural anticoagulant (Yoon et al., 2003; Bian et al., 2022). They also regulate endothelial mediators (eNOS, endothelin-1, prostacyclin, thromboxane B2) that control platelet activation (Bian et al., 2022). Glucuronic acid residues on the polysaccharide are essential for the anticoagulant activity; removing them eliminates the effect (Yoon et al., 2003).

Can you take wood ear mushroom with blood thinners?

No clinical data exist on interactions between Auricularia and pharmaceutical anticoagulants or antiplatelet drugs. Since Auricularia polysaccharides show both antiplatelet and anticoagulant activity in animal studies, there is a theoretical risk of excessive bleeding when combined with drugs like warfarin, rivaroxaban, aspirin, or clopidogrel. This interaction has never been tested in humans. The safety gap is significant for anyone on anticoagulant therapy.

What is AAP-b2 from Auricularia?

AAP-b2 is a purified polysaccharide (molecular weight 12.02 kDa) isolated from Auricularia auricula fruiting bodies. It consists mainly of mannose (89.25 mol%), glucuronic acid (30.50 mol%), glucose, and xylose. In a carrageenan-induced mouse thrombosis model, AAP-b2 inhibited platelet aggregation, reduced thrombus size, and prolonged all three standard clotting times (APTT, PT, TT). It works through both antiplatelet mechanisms (eNOS/endothelin pathway) and anticoagulant mechanisms (antithrombin III/protein C) (Bian et al., 2022).

Is wood ear mushroom better than aspirin for blood clots?

This comparison cannot be made. Aspirin's antiplatelet effects have been validated in clinical trials involving hundreds of thousands of participants with decades of outcome data. Auricularia polysaccharides showed aspirin-like platelet inhibition in a single ex vivo rat test (Yoon et al., 2003). No human clinical trials have tested Auricularia for thrombosis prevention. The preclinical data show biological activity, but comparing this to aspirin's clinical evidence base is not scientifically valid.

How much wood ear mushroom would you need to thin blood?

The pharmacologically effective dose for humans is unknown. In animal studies, purified polysaccharide extracts (not whole mushroom) were used. Agarwal et al. (1982) used 1 gram of dried mushroom extracted in 15 mL water for in vitro platelet tests. The polysaccharide content of commercial wood ear mushroom varies by source, preparation, and cooking method. No human dose-response study has been conducted, and translating from purified extract concentrations to dietary mushroom portions involves too many unknown variables for a reliable estimate.

Sources & References

1. 1RTHM-00002·Agarwal, K C et al. (1982). “Inhibition of human and rat platelet aggregation by extracts of Mo-er (Auricularia auricula)..” Thrombosis and haemostasis.Study breakdown →PubMed →↩
2. 2RTHM-00065·Yoon, Seon-Joo et al. (2003). “The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin..” Thrombosis research.Study breakdown →PubMed →↩
3. 3RTHM-00609·Bian, Chun et al. (2020). “Extraction Optimization, Structural Characterization, and Anticoagulant Activity of Acidic Polysaccharides from Auricularia auricula-judae..” Molecules (Basel.Study breakdown →PubMed →↩
4. 4RTHM-00744·Bian, Chun et al. (2022). “A Novel Polysaccharide from AuriculariaAuricula Alleviates Thrombosis Induced by Carrageenan in Mice..” Molecules (Basel.Study breakdown →PubMed →↩